Stepan VP granted SAR, RSU and performance shares

Stepan Company executive Sean Thomas Moriarty, VP & GM Surfactants, reported multiple equity awards.

Rhea-AI Filing Summary

Stepan Company executive Sean Thomas Moriarty, VP & GM Surfactants, reported multiple equity awards. On March 2, 2026, he was granted 7,155 Stock Appreciation Rights that vest ratably over three years, 4,495 Restricted Stock Units, and 2,247 performance shares, each representing a contingent right to one share of Stepan common stock.

The performance shares vest upon certification that Stepan achieved specified performance goals for the period ending December 31, 2028. On February 27, 2026, he also acquired 56.765 shares of common stock at $52.5100 per share. The filing notes an additional 4,478.3510 common shares held indirectly through an ESOP II Trust.

Insider Trade Summary

Grant/Award: 13,953.765 shares

Grant/Award 5 txns

Insider Moriarty Sean Thomas

Role VP & GM Surfactants

Type	Security	Shares	Price	Value
Grant/Award	Stock Appreciation Right	7,155	$0.00	$0.00
Grant/Award	Restricted Stock Units	4,495	$0.00	$0.00
Grant/Award	Performance Shares	2,247	$0.00	$0.00
Grant/Award	Common Stock	56.765	$52.51	$3K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Appreciation Right — 7,155 contracts (Direct); Restricted Stock Units — 4,495 contracts (Direct); Performance Shares — 2,247 contracts (Direct); Common Stock — 14,205.2335 shares (Direct); Common Stock — 4,478.351 shares (Indirect, By ESOP II Trust)

Footnotes (4)

1. F1. Vest ratably over three years beginning on the date shown.
2. F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Stepan Company common stock.
3. F3. Each performance share represents a contingent right to receive one share of Stepan Company common stock.
4. F4. The performance shares vest upon the certification of Stepan Company achieving certain performance goals for the performance period ending December 31, 2028.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Stepan (SCL) executive Sean Moriarty receive?

Sean Moriarty received several equity awards, including 7,155 Stock Appreciation Rights, 4,495 Restricted Stock Units, and 2,247 performance shares. All were granted on March 2, 2026, as part of his compensation in Stepan Company common stock-linked instruments.

How do Sean Moriarty’s Restricted Stock Units at Stepan (SCL) work?

Each of Sean Moriarty’s 4,495 Restricted Stock Units represents a contingent right to receive one share of Stepan Company common stock. These units vest ratably over three years beginning on the March 2, 2026 grant date, aligning value with continued service.

What are the terms of Sean Moriarty’s performance shares at Stepan (SCL)?

Sean Moriarty’s 2,247 performance shares each represent a contingent right to one Stepan common share. They vest only after certification that Stepan achieved specified performance goals for the performance period ending December 31, 2028, tying value directly to company performance.

Did Sean Moriarty acquire Stepan (SCL) common stock in this Form 4?

Yes. On February 27, 2026, Sean Moriarty acquired 56.765 shares of Stepan common stock at $52.5100 per share. This transaction increased his directly held common stock position as reported in the Form 4 filing data.

What indirect Stepan (SCL) share holdings are reported for Sean Moriarty?

The Form 4 reports 4,478.3510 Stepan common shares held indirectly for Sean Moriarty through an ESOP II Trust. This indirect ownership is separate from his directly held shares and from the newly granted derivative equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 07:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moriarty Sean Thomas

(Last) (First) (Middle)

1101 SKOKIE BOULEVARD, SUITE 500

(Street)

NORTHBROOK IL 60062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STEPAN CO [ SCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP & GM Surfactants

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		56.765	A	$52.51	14,205.2335	D
Common Stock								4,478.351	I	By ESOP II Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Right	$17.47	03/02/2026		A		7,155		03/02/2027(1)	03/03/2036	Common Stock	7,155	$0	7,155	D
Restricted Stock Units	(2)	03/02/2026		A		4,495		03/02/2027(1)	03/02/2029	Restricted Stock Units	4,495	$0	4,495	D
Performance Shares	(3)	03/02/2026		A		2,247		(4)	(4)	Common Stock	2,247	$0	2,247	D

Explanation of Responses:

1. Vest ratably over three years beginning on the date shown.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Stepan Company common stock.

3. Each performance share represents a contingent right to receive one share of Stepan Company common stock.

4. The performance shares vest upon the certification of Stepan Company achieving certain performance goals for the performance period ending December 31, 2028.

	/s/ James A. HArt, Attorney-in-Fact for Sean T. Moriarty	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.